Introduction. Non-Hodgkin’s lymphoma (NHL) shows clonal and uncontrolled proliferation of immature lymphoid precursors.
The aim of the study. Dynamic analysis of immunobiological and immunophenotypic parameters in the treatment of patients with NHL, and recognition of immunological remissions.
Material and methods. The retrospective study group consisted of 122 patients, admitted between 2012 and 2015 in the Hematology Clinic of the Republic of Moldova Oncology Institute, with a morphologically confirmed diagnosis of NHL. We assessed the predominant phenotypic line by indirect immunophenotyping and total concentration of immunoglobulin classes (A, M, G) according to treatment regimens applied to NHL patients.
Results. 119 patients showed CD19 antigen and CD20 increased expression of cell line B phenotype (84.4%); only 3 patients in the study showed increased CD3, CD5, resulting in the predominant T-cell phenotype line. NHL patients with both aggressive and non-aggressive primary variants after 3 cycles and 6 cycles presented a significant decrease in immunoglobulin A, M, and G indices, on average of 7.3±0.2(mg/ml) (p˂0.05), while the immunological indices of patients treated with the polychemotherapy (PTCH) scheme 2 reported statistically significant minimal decreases (p <0.05), setting an incomplete immunological remission.
Conclusions. Due to the information obtained by periodic monitoring of patients with NHL following the termination of conventional clinical protocols, it was possible to reveal the immunological and immunophenotypic features of the disease, for the detection of early and late recurrences, late side effects, occurrence of the second malignancy, with the evaluation of the immunological and immunophenotypic remission and identification of specific molecular targets for subsequent targeted therapy.
Keywords: polychemotherapy, non-Hodgkin’s lymphoma, target treatment, monoclonal antibodies, immunoglobulins.
List of abbreviations:
NHL – Non-Hodgkin’s lymphoma
mAb – monoclonal antibodies
PCHT – polychemotherapy
Ig – immunoglobulins
Address for correspondence:
Public Health Institution Institute of Oncology, Chisinau, Republic of Moldova
Email: firstname.lastname@example.org; Phone 068599004